BioSpace News Archive

Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.

Venus Concept Inc. , announced today that first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024.

CVRx, Inc., a commercial-stage medical device company, announced the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure.

Invivyd, Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code covering product reimbursement for PEMGARDA.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.

Soligenix, Inc. announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for “the prevention and post-exposure prophylaxis against MARV infection.”

Vasomune Therapeutics, Inc. has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS).

Spinogenix, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SPG601 for the treatment of people with Fragile X Syndrome (FXS).

Corcept Therapeutics Incorporated today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).

Daxor Corporation announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024.